Harwanegg Christian, Hiller Reinhard
VBC - Genomics Bioscience Research, Rennweg 95 B, 1030 Vienna, Austria.
Expert Rev Mol Diagn. 2004 Jul;4(4):539-48. doi: 10.1586/14737159.4.4.539.
Over the last few decades, the prevalence of allergic diseases has increased dramatically in developed nations. The resulting worldwide burden on healthcare systems has provoked a whole series of research initiatives among allergy experts and commercial companies that aim to develop novel tests to improve the diagnostic risk assessment and early preventive treatment of disease. The advent of protein microarray technology has fueled aspirations of multianalyte immunological applications that permit the simultaneous analysis of huge numbers of disease-related parameters that will hopefully become amenable in the near future. Allergen microarrays have been developed for the monitoring of patient-specific antibody profiles to a previously unknown variety of allergens in a single analytical step. This review describes significant discoveries and developments in allergy research against a background of the increasing prevalence of disease and hence the emerging challenges for national healthcare systems. The development of novel protein microarray-based allergy diagnostic tests is portrayed in concert with the recent advances and benefits of this technology, along with the challenges that must be met by manufacturers in order to succeed with innovative allergen microarrays in a highly competitive market.
在过去几十年中,过敏性疾病在发达国家的患病率急剧上升。由此给全球医疗系统带来的负担引发了过敏症专家和商业公司的一系列研究倡议,旨在开发新的检测方法,以改善疾病的诊断风险评估和早期预防性治疗。蛋白质微阵列技术的出现激发了人们对多分析物免疫应用的期望,这种应用能够同时分析大量与疾病相关的参数,有望在不久的将来实现。过敏原微阵列已被开发出来,用于在单个分析步骤中监测患者针对多种先前未知过敏原的特异性抗体谱。本综述在疾病患病率不断上升以及国家医疗系统面临新挑战的背景下,描述了过敏研究中的重大发现和进展。新型基于蛋白质微阵列的过敏诊断检测方法的开发与该技术的最新进展和优势一同呈现,同时还介绍了制造商在竞争激烈的市场中成功推出创新型过敏原微阵列所必须应对的挑战。